share_log

Altimmune analyst ratings

Altimmune analyst ratings

Altimmune分析師評級
Benzinga Analyst Ratings ·  2022/05/18 06:41
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
05/18/2022 372.59% Piper Sandler $34 → $25 Maintains Overweight
06/30/2021 296.98% B. Riley Securities $41 → $21 Maintains Buy
06/30/2021 486.01% JMP Securities $53 → $31 Maintains Market Outperform
06/30/2021 372.59% HC Wainwright & Co. $35 → $25 Maintains Buy
06/16/2021 901.89% JMP Securities $45 → $53 Maintains Market Outperform
06/02/2021 561.63% HC Wainwright & Co. → $35 Initiates Coverage On → Buy
02/11/2021 580.53% Guggenheim → $36 Initiates Coverage On → Buy
11/24/2020 372.59% Evercore ISI Group → $25 Reinstates → Outperform
09/25/2020 486.01% B. Riley Securities → $31 Initiates Coverage On → Buy
07/31/2020 1412.29% Piper Sandler → $80 Initiates Coverage On → Overweight
07/28/2020 845.18% JMP Securities → $50 Initiates Coverage On → Market Outperform
07/19/2019 56.9% Roth Capital → $8.3 Initiates Coverage On → Buy
10/09/2017 13.42% Piper Sandler → $6 Initiates Coverage On → Overweight
日期 上行/下行 分析公司 目標價格變化 評級變化 上一次/當前評級
05/18/2022 372.59% 派珀·桑德勒 $34 → $25 維護 超重
06/30/2021 296.98% B.萊利證券 $41 → $21 維護 買
06/30/2021 486.01% JMP證券 $53 → $31 維護 市場表現強於大盤
06/30/2021 372.59% HC Wainwright公司 $35 → $25 維護 買
06/16/2021 901.89% JMP證券 $45 → $53 維護 市場表現強於大盤
06/02/2021 561.63% HC Wainwright公司 → $35 開始承保 →購買
02/11/2021 580.53% 古根海姆 → $36 開始承保 →購買
11/24/2020 372.59% Evercore ISI集團 → $25 恢復 →跑贏大盤
09/25/2020 486.01% B.萊利證券 → $31 開始承保 →購買
07/31/2020 1412.29% 派珀·桑德勒 → $80 開始承保 →超重
07/28/2020 845.18% JMP證券 → $50 開始承保 →市場跑贏大盤
07/19/2019 56.9% 羅斯資本 → $8.3 開始承保 →購買
10/09/2017 13.42% 派珀·桑德勒 → $6 開始承保 →超重

Altimmune Questions & Answers

Altimmune問答

What is the target price for Altimmune (ALT)?
Altimmune(ALT)的目標價是多少？

The latest price target for Altimmune (NASDAQ: ALT) was reported by Piper Sandler on May 18, 2022. The analyst firm set a price target for $25.00 expecting ALT to rise to within 12 months (a possible 372.59% upside). 6 analyst firms have reported ratings in the last year.

派珀·桑德勒於2022年5月18日報道了Altimmune(納斯達克：ALT)的最新目標價。這家分析公司將目標價定為25美元，預計ALT將在12個月內上漲至(可能上漲372.59%)。6家分析公司在過去一年公佈了評級。

What is the most recent analyst rating for Altimmune (ALT)?
Altimmune(ALT)的最新分析師評級是多少？

The latest analyst rating for Altimmune (NASDAQ: ALT) was provided by Piper Sandler, and Altimmune maintained their overweight rating.

分析師對Altimmune(納斯達克代碼：ALT)的最新評級由Piper Sandler提供，Altimmune維持其增持評級。

When is the next analyst rating going to be posted or updated for Altimmune (ALT)?
Altimmune(ALT)的下一次分析師評級將於何時發佈或更新？

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Altimmune, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Altimmune was filed on May 18, 2022 so you should expect the next rating to be made available sometime around May 18, 2023.

分析師在進行了廣泛的研究後得出了股票評級，其中包括查閲公共財務報表，與Altimmune的高管和客户交談，以及收聽收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Altimmune的最後一次評級是在2022年5月18日提交的，所以你應該預計下一次評級將在2023年5月18日左右的某個時候公佈。

Is the Analyst Rating Altimmune (ALT) correct?
分析師對Altimmune(ALT)的評級正確嗎？

While ratings are subjective and will change, the latest Altimmune (ALT) rating was a maintained with a price target of $34.00 to $25.00. The current price Altimmune (ALT) is trading at is $5.29, which is out of the analyst's predicted range.

雖然評級是主觀的，並將發生變化，但最新的Altimmune(ALT)評級維持不變，目標價在34.00美元至25.00美元之間。Altimmune(ALT)目前的交易價格為5.29美元，超出了分析師的預測區間。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論